Abstract: A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment

Abstract: A method for preparing a suspension of “size-controlled” gas-filled microvesicles by microfluidic manufacturing techniques, which comprises using a gaseous flow comprising a first gas having high solubility in water and a second gas having low 5 solubility in water.

Abstract: A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment.

Abstract: Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.

Abstract: The present invention relates to the field of ultrasound-mediated therapeutic treatments in combination with gas-filled microvesicles. It relates in particular to enhancing the efficacy of a combined therapeutic treatment of gas-filled microvesicles and ultrasound, by reducing the vasospasm effect caused by said therapeutic treatment.

Abstract: An embodiment includes analyzing a body part perfused with a contrast agent, which has been pre-administered as a bolus to circulate through the body-part with at least a first passage during an analysis interval. The analyzing includes providing at least one input signal indicative of a response to an interrogation signal of a corresponding location of the body part during the analysis interval, and fitting each input signal over the analysis interval by an instance of a combined bolus function of time, based on a combination of a first simple bolus function of time modeling the first passage of the contrast agent and at least one second simple bolus function of time each one modeling a corresponding second passage of the contrast agent.

Abstract: Use of a suspension of gas-filled microbubbles comprising a fatty acids di-ester of phosphatidylcholine (PC), a pegylated phos-phatidylethanolamines (PE-PEG) and a fatty acid in a therapeutic method, wherein said suspension is administered as subsequent boluses.

Abstract: The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a mixture of freeze-drying protecting components, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.

Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.

Abstract: A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment

Abstract: The present invention discloses a new efficient process for the preparation of the KDR-targeting peptide-phospholipid conjugate of formula (I), which can be useful in therapeutic and diagnostic compositions and particularly in the preparation of ultrasound contrast agents.

Abstract: The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a freeze-drying protecting component, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.

Abstract: A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment.

Abstract: Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.

Abstract: The present invention discloses a new efficient process for the preparation of the KDR-targeting peptide-phospholipid conjugate of formula (I), which can be useful in therapeutic and diagnostic compositions and particularly in the preparation of ultrasound contrast agents.

Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.

Abstract: A method of mixing a liquid composition that includes microparticles dispersed in an aqueous liquid carrier may involve a first premixing step and a second premixing step. During the first premixing step a receptacle is oscillated about a longitudinal axis clockwise and counter-clockwise from a first reference point through a first angle of rotation for a first period of time and at a first angular velocity. During the second premixing step the receptacle is oscillated about the longitudinal axis clockwise and counter-clockwise from a second reference point through a second angle of rotation for a second period of time and at a second angular velocity. In examples, the first angle of rotation is smaller than said second angle of rotation, and the first period of time is shorter than the second period of time.

Abstract: Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

Abstract: Suspension of gas-filled microvesicles comprising a targeting ligand for binding to KDR or VEGF/KDR complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine.

Abstract: Ultrasonic sonothrombolysis systems to produce two acoustic pressure levels of insonation during stroke therapy, mid/high acoustic pressure insonation directed to the site of a blood clot where microbubbles are present to induce microbubble-mediated blood clot lysis, and low acoustic insonation directed to the region surrounding the site of the blood clot where microbubbles are present to stimulate microvascular reperfusion of the surrounding tissue. The systems simultaneously produce blood clot lysis at the site of an occlusion and stimulate reperfusion of tissue affected by the occlusion.